This study is in progress, not accepting new patients
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Summary
- Eligibility
- for males ages 4-7 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sarepta Therapeutics, Inc.
- ID
- NCT05096221
- Phase
- Phase 3 Duchenne Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- About 126 people participating
- Last Updated